Credit Suisse Group Analysts Give Sanofi (SAN) a €95.00 Price Target

Sanofi (EPA:SAN) has been assigned a €95.00 ($117.28) price target by stock analysts at Credit Suisse Group in a note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Credit Suisse Group’s price objective indicates a potential upside of 49.87% from the stock’s current price.

A number of other research firms have also weighed in on SAN. Jefferies Group set a €90.00 ($111.11) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Monday, October 16th. Goldman Sachs Group set a €82.00 ($101.23) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Tuesday, October 17th. Deutsche Bank set a €96.00 ($118.52) target price on shares of Sanofi and gave the stock a “buy” rating in a report on Wednesday, October 18th. UBS Group set a €82.00 ($101.23) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Monday, October 23rd. Finally, JPMorgan Chase & Co. set a €85.00 ($104.94) target price on shares of Sanofi and gave the stock a “neutral” rating in a report on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of €84.63 ($104.48).

Sanofi (EPA SAN) traded down €1.70 ($2.10) during mid-day trading on Thursday, hitting €63.39 ($78.26). 4,980,000 shares of the stock were exchanged, compared to its average volume of 2,940,000. The company has a market cap of $80,070.00 and a PE ratio of 20.99. Sanofi has a one year low of €63.09 ($77.89) and a one year high of €92.97 ($114.78).

ILLEGAL ACTIVITY WARNING: “Credit Suisse Group Analysts Give Sanofi (SAN) a €95.00 Price Target” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/11/credit-suisse-group-analysts-give-sanofi-san-a-95-00-price-target.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (EPA:SAN)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply